Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Maybe try reading the news release? Right your one of those
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(63)
•••
Comment by Bvukmanicon Jan 17, 2021 3:13pm
124 Views
Post# 32315945

RE:RE:RE:RE:RE:RE:RE:Maybe try reading the news release? Right your one of those

RE:RE:RE:RE:RE:RE:RE:Maybe try reading the news release? Right your one of thoseAre you serious? Literally everything she said was wrong. There's no evidence the two current mRNA vaccines are ineffective against the new strains. If a variant emerges that is resistant, the vaccines can easily be changed - similar to a flu shot, and they won't need additional safety studies. These vaccines only took days to actually develop after the original genome was sequenced. New antibodies cross reacting, stability, blah blah blah is complete gibberish. Who is she to doubt Pzifer, Moderna? Not surprised three people agreed with her, this board is filled with buffoons.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities